Metropolis is one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan). With operations across India, Africa, South Asia and Middle East.
Our globally accredited clinical laboratories deliver millions of accurate and timely test results every year. We offer a comprehensive range of clinical laboratory tests and profiles which are used in prediction, early detection, diagnostic screening, confirmation and monitoring of diseases.
Metropolis Healthcare Limited is proposing subject to applicable statutory or regulatory requirements, receipt of requisite approvals, market conditions and other considerations to undertake an initial public offering of its equity shares and has filed a draft red herring prospectus dated September 27, 2018 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of the SEBI at www.sebi.gov.in, BSE Limited at www.bseindia.com, National Stock Exchange of India Limited at www.nseindia.com and the websites of Book Running Lead Managers at www.jmfl.com, www.credit-suisse.com, www.investmentbank.kotak.com, www.hdfcbank.com and www.goldmansachs.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to same, please refer to the DRHP including the section “Risk Factors” of the DRHP. Potential investors should not rely on the DRHP filed with the SEBI for making any investment decision.